Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (11538)	11/20/1997 5:35:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Peter, Prandin sounds underdeveloped, in one of the references a clinician mentioned their lack of even a clear dose. Prandin works stimulating insulin production, it is not known the exact mechanisms. This limit the drug to type II diabetic, and it is similar to the sulfonilureas in the market. Not a big advancement. Plus the three times a day timing of doses, and the uncertainty of hypoglycemic episodes (not confirmed, but still suspected. Competition to every drug? Not necessarily, It does not address the Insulin resistance typeII well, just more insulin the other drugs do it untill you get a sicker pancreas. Targretin works at the endpoint of glucose use in the actual cells that uses the glucose. At least, at the metabolic level there is not competition, especially with the antiobesity and proheart effects of Targretin. Prandin seems to me that it will have a tendency to induced or not reduced obesity (speculation). And they could be use together (speculation) in lower doses (speculation), because of the different points of action (fact).